Concepts (258)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart-Assist Devices | 46 | 2023 | 731 | 8.000 |
Why?
|
| Heart Failure | 41 | 2024 | 1204 | 5.650 |
Why?
|
| Heart Transplantation | 21 | 2024 | 705 | 2.930 |
Why?
|
| Stroke | 16 | 2022 | 965 | 1.820 |
Why?
|
| Thrombosis | 10 | 2018 | 296 | 1.250 |
Why?
|
| Registries | 5 | 2023 | 702 | 1.120 |
Why?
|
| Thoracic Surgery | 2 | 2023 | 43 | 0.950 |
Why?
|
| Retrospective Studies | 31 | 2024 | 8489 | 0.880 |
Why?
|
| Patient Isolation | 1 | 2020 | 11 | 0.750 |
Why?
|
| Heart | 2 | 2023 | 539 | 0.750 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2019 | 10 | 0.710 |
Why?
|
| Heart Aneurysm | 1 | 2019 | 22 | 0.700 |
Why?
|
| Treatment Outcome | 26 | 2023 | 7993 | 0.700 |
Why?
|
| Surgeons | 1 | 2023 | 238 | 0.690 |
Why?
|
| Equipment Failure | 3 | 2018 | 119 | 0.660 |
Why?
|
| Humans | 72 | 2024 | 86643 | 0.640 |
Why?
|
| Betacoronavirus | 1 | 2020 | 258 | 0.590 |
Why?
|
| Prosthesis Implantation | 2 | 2017 | 125 | 0.590 |
Why?
|
| Middle Aged | 40 | 2023 | 25028 | 0.570 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2018 | 134 | 0.570 |
Why?
|
| Mortality | 1 | 2017 | 149 | 0.570 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 2018 | 68 | 0.530 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 316 | 0.510 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 301 | 0.510 |
Why?
|
| Hospitals | 1 | 2017 | 294 | 0.510 |
Why?
|
| Prosthesis Design | 8 | 2020 | 278 | 0.490 |
Why?
|
| Electric Power Supplies | 1 | 2014 | 9 | 0.490 |
Why?
|
| Pandemics | 1 | 2020 | 740 | 0.480 |
Why?
|
| Male | 42 | 2023 | 40965 | 0.450 |
Why?
|
| Postoperative Complications | 6 | 2022 | 2207 | 0.440 |
Why?
|
| Tissue Donors | 7 | 2024 | 463 | 0.430 |
Why?
|
| Lung Transplantation | 4 | 2022 | 175 | 0.420 |
Why?
|
| Waiting Lists | 4 | 2023 | 175 | 0.410 |
Why?
|
| Aged | 24 | 2022 | 18415 | 0.410 |
Why?
|
| Kaplan-Meier Estimate | 9 | 2022 | 860 | 0.400 |
Why?
|
| Agricultural Workers' Diseases | 1 | 2011 | 18 | 0.390 |
Why?
|
| Commerce | 1 | 2011 | 29 | 0.390 |
Why?
|
| Agriculture | 1 | 2011 | 38 | 0.390 |
Why?
|
| Mitral Valve Insufficiency | 2 | 2020 | 187 | 0.380 |
Why?
|
| Hemodynamics | 5 | 2023 | 710 | 0.370 |
Why?
|
| Female | 38 | 2023 | 44532 | 0.370 |
Why?
|
| Survival Rate | 8 | 2017 | 1863 | 0.360 |
Why?
|
| Extracorporeal Membrane Oxygenation | 3 | 2022 | 139 | 0.340 |
Why?
|
| Proportional Hazards Models | 6 | 2018 | 859 | 0.340 |
Why?
|
| Follow-Up Studies | 10 | 2022 | 3640 | 0.330 |
Why?
|
| Leukemia | 1 | 2011 | 320 | 0.330 |
Why?
|
| Organ Preservation | 3 | 2024 | 83 | 0.330 |
Why?
|
| Risk Factors | 11 | 2019 | 5417 | 0.300 |
Why?
|
| Sternum | 1 | 2006 | 30 | 0.280 |
Why?
|
| Shock, Cardiogenic | 2 | 2017 | 95 | 0.280 |
Why?
|
| Heart Valve Prosthesis Implantation | 3 | 2023 | 166 | 0.270 |
Why?
|
| Vascular Diseases | 1 | 2007 | 121 | 0.270 |
Why?
|
| Thorax | 2 | 2023 | 75 | 0.270 |
Why?
|
| Equipment Design | 3 | 2022 | 406 | 0.270 |
Why?
|
| Adult | 20 | 2024 | 25648 | 0.260 |
Why?
|
| Heart Ventricles | 3 | 2023 | 760 | 0.260 |
Why?
|
| Time Factors | 10 | 2019 | 5210 | 0.260 |
Why?
|
| Odds Ratio | 3 | 2017 | 678 | 0.250 |
Why?
|
| Severity of Illness Index | 6 | 2019 | 1801 | 0.240 |
Why?
|
| Cardiac Valve Annuloplasty | 1 | 2023 | 13 | 0.240 |
Why?
|
| Atrioventricular Block | 1 | 2023 | 23 | 0.230 |
Why?
|
| Ventricular Function, Left | 3 | 2019 | 592 | 0.230 |
Why?
|
| Cohort Studies | 5 | 2022 | 2767 | 0.220 |
Why?
|
| Brain Death | 1 | 2023 | 69 | 0.220 |
Why?
|
| Mitral Valve | 2 | 2020 | 248 | 0.220 |
Why?
|
| Hospitalization | 4 | 2023 | 849 | 0.210 |
Why?
|
| Societies, Medical | 2 | 2023 | 572 | 0.210 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2023 | 130 | 0.210 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2023 | 111 | 0.210 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2022 | 44 | 0.210 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2022 | 93 | 0.190 |
Why?
|
| Prospective Studies | 8 | 2024 | 4213 | 0.190 |
Why?
|
| Enoxaparin | 1 | 2020 | 23 | 0.190 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2020 | 29 | 0.190 |
Why?
|
| Multivariate Analysis | 3 | 2018 | 999 | 0.180 |
Why?
|
| Heparin | 1 | 2020 | 175 | 0.180 |
Why?
|
| Databases, Factual | 1 | 2023 | 814 | 0.180 |
Why?
|
| Graft Survival | 4 | 2024 | 884 | 0.180 |
Why?
|
| Photopheresis | 1 | 1999 | 12 | 0.180 |
Why?
|
| Prognosis | 4 | 2022 | 3679 | 0.180 |
Why?
|
| United States | 5 | 2020 | 6672 | 0.170 |
Why?
|
| Tissue and Organ Procurement | 1 | 2023 | 311 | 0.170 |
Why?
|
| Thoracotomy | 1 | 2018 | 58 | 0.160 |
Why?
|
| Hepatitis C, Chronic | 1 | 2019 | 126 | 0.160 |
Why?
|
| Lung Diseases, Fungal | 1 | 1998 | 17 | 0.160 |
Why?
|
| Postoperative Hemorrhage | 1 | 2018 | 46 | 0.160 |
Why?
|
| Anticoagulants | 2 | 2020 | 408 | 0.160 |
Why?
|
| Heart Valve Prosthesis | 2 | 2014 | 93 | 0.160 |
Why?
|
| Aspergillosis | 1 | 1998 | 41 | 0.160 |
Why?
|
| Hemolysis | 2 | 2017 | 61 | 0.160 |
Why?
|
| Intracranial Hemorrhages | 1 | 2019 | 120 | 0.160 |
Why?
|
| Graft Rejection | 2 | 2004 | 1065 | 0.150 |
Why?
|
| Hepatitis C | 1 | 2019 | 208 | 0.150 |
Why?
|
| Immunocompromised Host | 1 | 1998 | 140 | 0.150 |
Why?
|
| Magnets | 1 | 2017 | 14 | 0.150 |
Why?
|
| Brain Ischemia | 2 | 2019 | 398 | 0.150 |
Why?
|
| Algorithms | 3 | 2018 | 1830 | 0.140 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1998 | 261 | 0.140 |
Why?
|
| Reoperation | 4 | 2019 | 597 | 0.140 |
Why?
|
| Esophageal Neoplasms | 1 | 1998 | 321 | 0.140 |
Why?
|
| Health Services Accessibility | 1 | 2018 | 394 | 0.130 |
Why?
|
| Disease-Free Survival | 4 | 2019 | 1204 | 0.130 |
Why?
|
| Cause of Death | 1 | 2015 | 277 | 0.120 |
Why?
|
| Aged, 80 and over | 5 | 2019 | 6509 | 0.120 |
Why?
|
| Intention to Treat Analysis | 3 | 2019 | 72 | 0.120 |
Why?
|
| Coronary Vessels | 3 | 2008 | 177 | 0.120 |
Why?
|
| Delivery of Health Care | 1 | 2018 | 426 | 0.120 |
Why?
|
| Heart Valve Diseases | 1 | 2014 | 109 | 0.110 |
Why?
|
| Italy | 1 | 2011 | 106 | 0.100 |
Why?
|
| Sex Distribution | 1 | 2011 | 173 | 0.090 |
Why?
|
| Extracorporeal Circulation | 2 | 2022 | 26 | 0.090 |
Why?
|
| Incidence | 2 | 2014 | 1577 | 0.090 |
Why?
|
| Patient Selection | 3 | 2016 | 685 | 0.090 |
Why?
|
| Life Style | 1 | 2011 | 189 | 0.090 |
Why?
|
| Sex Factors | 3 | 2018 | 1054 | 0.090 |
Why?
|
| Prosthesis Failure | 3 | 2019 | 111 | 0.090 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 1673 | 0.090 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2014 | 462 | 0.080 |
Why?
|
| Materials Testing | 2 | 2018 | 91 | 0.080 |
Why?
|
| Hospital Mortality | 2 | 2021 | 349 | 0.080 |
Why?
|
| Age Factors | 3 | 2017 | 1851 | 0.080 |
Why?
|
| Epidemiologic Methods | 1 | 2007 | 59 | 0.070 |
Why?
|
| Postoperative Care | 2 | 2006 | 221 | 0.070 |
Why?
|
| Adolescent | 4 | 2021 | 8981 | 0.070 |
Why?
|
| Lung | 3 | 2022 | 1170 | 0.070 |
Why?
|
| Combined Modality Therapy | 3 | 1999 | 1686 | 0.070 |
Why?
|
| Myocarditis | 1 | 2006 | 50 | 0.070 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2006 | 92 | 0.070 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2005 | 72 | 0.060 |
Why?
|
| Aortic Aneurysm | 1 | 2005 | 80 | 0.060 |
Why?
|
| Aorta, Thoracic | 1 | 2006 | 165 | 0.060 |
Why?
|
| Aorta | 1 | 2005 | 280 | 0.060 |
Why?
|
| Echocardiography, Doppler | 1 | 2005 | 187 | 0.060 |
Why?
|
| Coronary Artery Bypass | 2 | 2023 | 228 | 0.060 |
Why?
|
| Aortic Valve | 1 | 2005 | 222 | 0.060 |
Why?
|
| Wound Healing | 1 | 2006 | 344 | 0.060 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2004 | 190 | 0.060 |
Why?
|
| Pneumonectomy | 2 | 1998 | 196 | 0.060 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2005 | 208 | 0.060 |
Why?
|
| Tricuspid Valve | 1 | 2023 | 96 | 0.060 |
Why?
|
| Death | 1 | 2023 | 73 | 0.050 |
Why?
|
| Heart Arrest | 1 | 2006 | 265 | 0.050 |
Why?
|
| Islets of Langerhans Transplantation | 1 | 2004 | 225 | 0.050 |
Why?
|
| Cardiac Output | 1 | 2022 | 156 | 0.050 |
Why?
|
| Coronary Artery Disease | 1 | 2007 | 350 | 0.050 |
Why?
|
| Perfusion | 1 | 2022 | 203 | 0.050 |
Why?
|
| Propensity Score | 1 | 2022 | 136 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2022 | 159 | 0.050 |
Why?
|
| Catheters | 1 | 2022 | 74 | 0.050 |
Why?
|
| Body Size | 1 | 2022 | 91 | 0.050 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2022 | 78 | 0.050 |
Why?
|
| Young Adult | 3 | 2018 | 5976 | 0.050 |
Why?
|
| Kansas | 1 | 2020 | 6 | 0.050 |
Why?
|
| Indiana | 1 | 2020 | 12 | 0.050 |
Why?
|
| Cardiovascular Diseases | 1 | 2008 | 827 | 0.050 |
Why?
|
| International Normalized Ratio | 1 | 2020 | 38 | 0.050 |
Why?
|
| Patient Safety | 1 | 2023 | 212 | 0.050 |
Why?
|
| Patient Discharge | 1 | 2023 | 300 | 0.050 |
Why?
|
| CD59 Antigens | 1 | 2000 | 17 | 0.050 |
Why?
|
| Postoperative Period | 1 | 2020 | 303 | 0.040 |
Why?
|
| Resource Allocation | 1 | 2020 | 65 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2019 | 2261 | 0.040 |
Why?
|
| Forced Expiratory Volume | 1 | 1999 | 122 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2020 | 916 | 0.040 |
Why?
|
| Transplantation, Heterologous | 1 | 2000 | 363 | 0.040 |
Why?
|
| Hepacivirus | 1 | 2019 | 159 | 0.040 |
Why?
|
| Recurrence | 2 | 1998 | 1139 | 0.040 |
Why?
|
| Child | 2 | 2021 | 6927 | 0.040 |
Why?
|
| Walk Test | 1 | 2018 | 21 | 0.040 |
Why?
|
| Disability Evaluation | 1 | 2019 | 136 | 0.040 |
Why?
|
| Costs and Cost Analysis | 1 | 2018 | 153 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 1998 | 220 | 0.040 |
Why?
|
| Neutropenia | 1 | 1998 | 215 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 1998 | 117 | 0.040 |
Why?
|
| Radiotherapy Dosage | 1 | 1998 | 468 | 0.040 |
Why?
|
| Tachycardia, Ventricular | 1 | 1998 | 115 | 0.040 |
Why?
|
| Bone Marrow Transplantation | 1 | 1998 | 286 | 0.040 |
Why?
|
| Heart Septum | 1 | 1997 | 45 | 0.040 |
Why?
|
| Transplantation, Autologous | 1 | 1998 | 331 | 0.040 |
Why?
|
| Heart Arrest, Induced | 1 | 1996 | 31 | 0.040 |
Why?
|
| Neutrophils | 1 | 1998 | 307 | 0.040 |
Why?
|
| Pulmonary Embolism | 1 | 1999 | 222 | 0.040 |
Why?
|
| Patient Readmission | 1 | 2020 | 329 | 0.040 |
Why?
|
| Swine | 3 | 2004 | 555 | 0.030 |
Why?
|
| Morbidity | 1 | 2016 | 148 | 0.030 |
Why?
|
| Stress, Mechanical | 1 | 2017 | 248 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2019 | 510 | 0.030 |
Why?
|
| Transplantation, Homologous | 1 | 1998 | 996 | 0.030 |
Why?
|
| Device Removal | 1 | 2017 | 161 | 0.030 |
Why?
|
| Echocardiography | 1 | 2020 | 911 | 0.030 |
Why?
|
| Membrane Glycoproteins | 1 | 1997 | 428 | 0.030 |
Why?
|
| Risk | 1 | 2016 | 674 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 1999 | 977 | 0.030 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 1997 | 318 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 1997 | 376 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 1997 | 532 | 0.030 |
Why?
|
| Ventricular Function, Right | 1 | 2014 | 142 | 0.030 |
Why?
|
| Lung Neoplasms | 2 | 1997 | 2262 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2018 | 1143 | 0.030 |
Why?
|
| Immunoglobulin M | 2 | 2004 | 154 | 0.030 |
Why?
|
| Child, Preschool | 1 | 1998 | 3612 | 0.020 |
Why?
|
| Preoperative Care | 2 | 2006 | 397 | 0.020 |
Why?
|
| Quality of Life | 1 | 2018 | 1585 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2014 | 1169 | 0.020 |
Why?
|
| Washington | 1 | 2008 | 48 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 1998 | 2438 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 2601 | 0.020 |
Why?
|
| Giant Cells | 1 | 2006 | 19 | 0.020 |
Why?
|
| Rupture | 1 | 2006 | 63 | 0.020 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2005 | 46 | 0.020 |
Why?
|
| Rats, Inbred Lew | 1 | 2005 | 186 | 0.020 |
Why?
|
| Tyrosine | 1 | 2005 | 133 | 0.020 |
Why?
|
| Cyclosporine | 1 | 2005 | 234 | 0.020 |
Why?
|
| Indoles | 1 | 2005 | 318 | 0.010 |
Why?
|
| Animals | 4 | 2005 | 26582 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2005 | 894 | 0.010 |
Why?
|
| Acute Disease | 1 | 2004 | 826 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2005 | 639 | 0.010 |
Why?
|
| Transplantation Conditioning | 1 | 2004 | 373 | 0.010 |
Why?
|
| Macaca mulatta | 1 | 2004 | 459 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 1961 | 0.010 |
Why?
|
| Heart Valves | 1 | 2000 | 13 | 0.010 |
Why?
|
| Complement Hemolytic Activity Assay | 1 | 2000 | 1 | 0.010 |
Why?
|
| Lung Compliance | 1 | 2000 | 14 | 0.010 |
Why?
|
| Complement C3a | 1 | 2000 | 11 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2004 | 873 | 0.010 |
Why?
|
| Vascular Resistance | 1 | 2000 | 102 | 0.010 |
Why?
|
| Pulmonary Circulation | 1 | 2000 | 86 | 0.010 |
Why?
|
| Safety | 1 | 2000 | 152 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2000 | 316 | 0.010 |
Why?
|
| Models, Animal | 1 | 2000 | 263 | 0.010 |
Why?
|
| Rats | 1 | 2005 | 3990 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 1992 | 2903 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2005 | 2232 | 0.010 |
Why?
|
| Hemorrhage | 1 | 2000 | 268 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2000 | 989 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2000 | 456 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 1998 | 399 | 0.010 |
Why?
|
| Fas Ligand Protein | 1 | 1997 | 49 | 0.010 |
Why?
|
| Rupture, Spontaneous | 1 | 1997 | 43 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 1997 | 87 | 0.010 |
Why?
|
| Myocardial Ischemia | 1 | 1998 | 162 | 0.010 |
Why?
|
| fas Receptor | 1 | 1997 | 75 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 1997 | 293 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 1997 | 265 | 0.010 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 1996 | 73 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1997 | 1041 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1997 | 1014 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1997 | 927 | 0.010 |
Why?
|
| Echocardiography, Transesophageal | 1 | 1997 | 344 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 1998 | 1823 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 1997 | 1981 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 1992 | 468 | 0.010 |
Why?
|
| Radiotherapy | 1 | 1992 | 328 | 0.010 |
Why?
|
| Mastectomy | 1 | 1992 | 243 | 0.010 |
Why?
|
| Academic Medical Centers | 1 | 1992 | 379 | 0.010 |
Why?
|
| Chicago | 1 | 1992 | 1379 | 0.000 |
Why?
|
| Neoplasm Staging | 1 | 1992 | 1939 | 0.000 |
Why?
|